Evidence map›Paper›PMID 40940971›Full record

ArticleCancers2025

Integration of Next-Generation Sequencing in Measurable Residual Disease Monitoring in Acute Myeloid Leukemia and Myelodysplastic Neoplasm.

Elena Crisà, Irene Dogliotti, Giuseppe Lia, Marco Cerrano, Ernesta Audisio, Giuseppe Lanzarone, Lucia Brunello, Daniela Caravelli, Fabrizio Carnevale Schianca, Enrico Berrino and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Elena CrisàCandiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.ORCID 0000-0003-1912-0574
Irene DogliottiDivision of Hematology U, University Hospital A.O.U. "Città della Salute e della Scienza", University of Turin, 10126 Torino, Italy.
Giuseppe LiaDepartment of Molecular Biotechnologies and Health Sciences, University of Torino, 10126 Torino, Italy.
Marco CerranoAzienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, 10126 Torino, Italy.
Ernesta AudisioAzienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, 10126 Torino, Italy.
Giuseppe LanzaroneDivision of Hematology U, University Hospital A.O.U. "Città della Salute e della Scienza", University of Turin, 10126 Torino, Italy.ORCID 0000-0002-8114-0798
Lucia BrunelloSCDU Ematologia, AOU SS Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy.
Daniela CaravelliCandiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Fabrizio Carnevale SchiancaCandiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Enrico BerrinoCandiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.ORCID 0000-0001-6728-5619
Sara Erika BellomoCandiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Alice BartoliniCandiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
Ludovica RieraMolecular Pathology Unit, AOU Città della Salute e della Scienza, 10126 Torino, Italy.
Paola Francia di CelleMolecular Pathology Unit, AOU Città della Salute e della Scienza, 10126 Torino, Italy.
Gianluca GaidanoDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont and AOU Maggiore della Carità, 28100 Novara, Italy.ORCID 0000-0002-4681-0151
Monia LunghiDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont and AOU Maggiore della Carità, 28100 Novara, Italy.
Luisa GiacconeDivision of Hematology U, University Hospital A.O.U. "Città della Salute e della Scienza", University of Turin, 10126 Torino, Italy.ORCID 0000-0002-0860-3266
Benedetto BrunoDivision of Hematology U, University Hospital A.O.U. "Città della Salute e della Scienza", University of Turin, 10126 Torino, Italy.ORCID 0000-0002-7299-6770

Funding

2021 EMAGEN xxxFPRC 5x1000 Ministero della Salute xxItalian Ministry of Health, Ricerca Corrente 2025 xxJanssen Pharmaceutical Companies of Johnson & Johnson xxx
6 · The paper itself

Abstract

BACKGROUND/

objectivesRecent evidence underscores the prognostic and classificatory relevance of somatic mutations in myelodysplastic neoplasms (MDSs) and acute myeloid leukemia (AML).

methodsThis prospective study assessed gene mutation dynamics via next-generation sequencing (NGS) in 84 MDS/AML patients treated with intensive chemotherapy or hypomethylating agents plus venetoclax.

resultsAt diagnosis, 95% had somatic mutations detected by NGS, while only 29% had a measurable residual disease (MRD) marker with qPCRs. NGS at complete remission (CR) was performed in 56/71 patients who achieved CR; 59% had persisting mutations, mostly in DNMT3A, TET2, and ASXL1 (DTA mutations). Mutations' persistence in CR was linked to a shorter relapse-free survival (RFS; median 8 months vs. not reached, HR 4.41, 95% CI 1.69-11.49;

conclusionsThis real-world study confirms the added prognostic role of NGS in MRD detection on RFS, particularly when combined with MFC. This approach may improve risk stratification and guide treatment decisions.

Indexed as

acute myeloid leukemiaallogeneic stem cell transplantationminimal residual diseasemyelodysplastic syndromesnext generation sequencing

Identifiers

PMID40940971
PMCPMC12427408

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.